Bristol Myers Squibb (BMY) Leases (2019 - 2026)

Bristol Myers Squibb has reported Leases over the past 8 years, most recently at $1.5 billion for Q1 2026.

Quarterly Leases rose 25.76% to $1.5 billion in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $1.5 billion through Mar 2026, up 25.76% year-over-year, with the annual reading at $1.6 billion for FY2025, 29.25% up from the prior year.
Leases was $1.5 billion for Q1 2026 at Bristol Myers Squibb, down from $1.6 billion in the prior quarter.
Over five years, Leases peaked at $1.6 billion in Q3 2025 and troughed at $840.0 million in Q2 2022.
The 5-year median for Leases is $1.3 billion (2024), against an average of $1.3 billion.
Year-over-year, Leases fell 16.5% in 2022 and then soared 54.81% in 2023.
A 5-year view of Leases shows it stood at $1.2 billion in 2022, then rose by 13.93% to $1.4 billion in 2023, then decreased by 11.94% to $1.2 billion in 2024, then grew by 29.25% to $1.6 billion in 2025, then dropped by 3.41% to $1.5 billion in 2026.
Per Business Quant, the three most recent readings for BMY's Leases are $1.5 billion (Q1 2026), $1.6 billion (Q4 2025), and $1.6 billion (Q3 2025).

Peer Comparison